Evaxion presents new preclinical findings related to an engineered cytomegalovirus (CMV) vaccine candidate. The information released by the company focuses on results from early, non-human studies evaluating the candidate designed using artificial intelligence approaches. Across the coverage, the central point is that Evaxion is disclosing preclinical (pre-clinical) data ahead of potential future steps toward human testing. The reporting describes the update as evidence supporting the vaccine candidate’s development and characterizes it as AI-designed, indicating that computational methods are being used in its design process. The articles do not indicate that the vaccine has entered clinical trials at the time of the announcements, and the details are framed around early-stage, laboratory or animal research. Overall, the sources agree that Evaxion’s announcement is a development milestone: it provides a public update on preclinical progress for its CMV vaccine program, with additional regulatory and clinical study steps implied as next milestones rather than reported as completed.